Last reviewed 2026-05-15 · How we verify

Anti-SARS-CoV-2 mAb

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19 (PHASE1)
• Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19) (PHASE2)
• The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19 (PHASE2, PHASE3)
• A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults (PHASE3)
• COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age (PHASE2)
• COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19 (PHASE1)
• COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers (PHASE1)
• Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Anti-SARS-CoV-2 mAb CI brief — competitive landscape report
• Anti-SARS-CoV-2 mAb updates RSS · CI watch RSS
• University of Calgary portfolio CI